Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $35,070.00 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 835 shares of Pro-Dex stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $42.00, for a total value of $35,070.00. Following the completion of the transaction, the director now owns 334,646 shares of the company’s stock, valued at approximately $14,055,132. The trade was a 0.25 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Pro-Dex Trading Down 2.9 %

NASDAQ:PDEX opened at $40.66 on Monday. Pro-Dex, Inc. has a 12-month low of $16.18 and a 12-month high of $59.60. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.41 and a quick ratio of 1.94. The business has a 50 day simple moving average of $47.76 and a 200 day simple moving average of $33.83. The firm has a market capitalization of $132.55 million, a P/E ratio of 26.40 and a beta of 0.56.

Analysts Set New Price Targets

Several analysts have weighed in on PDEX shares. StockNews.com upgraded shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 14th. Ascendiant Capital Markets boosted their price objective on shares of Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, November 11th.

Hedge Funds Weigh In On Pro-Dex

Several institutional investors have recently modified their holdings of the company. FMR LLC boosted its stake in Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after purchasing an additional 1,028 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Pro-Dex by 7.9% in the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock valued at $240,000 after acquiring an additional 900 shares in the last quarter. Bard Associates Inc. increased its stake in shares of Pro-Dex by 17.6% during the third quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock valued at $406,000 after acquiring an additional 2,031 shares during the period. Ritholtz Wealth Management bought a new stake in Pro-Dex during the fourth quarter worth approximately $572,000. Finally, JPMorgan Chase & Co. lifted its position in Pro-Dex by 2.2% in the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after purchasing an additional 529 shares during the period. Institutional investors own 15.28% of the company’s stock.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.